ASX Share rice
Wed 05 Aug 2020 - 11:27:pm (Sydney)

EX1 Share Price

EXOPHARM LIMITEDEX1Pharmaceuticals, Biotechnology & Life Sciences

EX1 Company Information

Name:

Exopharm Limited

Sector:

Healthcare

Industry:

Biotechnology

Address:

31 Queen Street Melbourne VIC Australia 3000

Phone:

61 3 9111 0026

Full Time Employees:

21

Company Founder, Technology Co-Founder, MD & Director:

Dr. Ian E. Dixon M.A.I.C.D., M.B.A., MBA, Ph.D.

COO & Technology Co-Founder:

Dr. Gregory Lichtfuss M.Sc.

Chief Commercial Officer:

Dr. Christopher Baldwin Ph.D.

Company Sec. & Director:

Ms. Sinead Teague L.L.B., M.Sc.

Company Overview:

Exopharm Limited, a biopharmaceutical company, focuses on developing and commercializing human therapeutics in Australia. The company is Plexaris and Exomere products, including non-clinical, pre-clinical, and clinical testing for other medical conditions, such as dry age-related macular degeneration and osteoarthritis. Exopharm Limited was founded in 2013 and is headquartered in Melbourne, Australia.

EX1 Share Price Information

Shares Issued:

95.47M

Market Capitalisation:

$24.82M

Revenue (TTM):

$38.87K

Earnings per Share:

$-0.04

Operating Margin (TTM):

$-132.87

Return On Assets (TTM):

$-0.51

Return On Equity (TTM):

$-0.89

Quarterly Revenue Growth (YOY):

30.697

Gross Profit(TTM):

$-496,688

Diluted Earnings Per Share (TTM):

$-0.065

EX1 CashFlow Statement

CashFlow Date:

2019-06-30

Investments:

$-858,652

Change To Liabilities:

$65.48K

Total Cashflow From Investing Activities:

$-858,652

Net Income:

$-2,282,874

Total Cash From Operating Activities:

$-2,184,519

Depreciation:

$60.01K

Capital Expenditures:

$858.65K

EX1 Income Statement

Income Date:

2019-06-30

Income Before Tax:

$-2,282,874

Net Income:

$-2,282,874

Gross Profit:

$-496,688

Operating Income:

$-2,311,663

Other Operating Expenses:

$451.28K

Total Revenue:

$28.79K

Total Operating Expenses:

$2.31M

Cost Of Revenue:

$496.69K

EX1 Balance Sheet

Balance Sheet Date:

2019-06-30

Intangible Assets:

$325K

Total Liabilities:

$281K

Total Stockholder Equity:

$5.12M

Other Current Liabilities:

$124.19K

Total Assets:

$5.40M

Common Stock:

$7.58M

Other Current Assets:

$162.51K

Retained Earnings:

$-2,459,232

Cash:

$4.42M

Total Current Liabilities:

$281K

Property - Plant & Equipment:

$494.12K

Net Tangible Assets:

$4.79M

Total Current Assets:

$4.58M

Net Receivables:

$51.13K

Short-Term Investments:

$819.12K

Accounts Payable:

$36.53K

Non Currrent Assets (Other):

$819.12K

Short-Term Investments:

$819.12

Non Current Liabilities Total:

$0

EX1 Share Price History

EX1 News

24 Feb, 2020
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
29 Jan, 2020
The first human dosing of PlexarisTM has occurred in Exopharm’s PLEXOVAL Study.
19 Dec, 2019
A leading developer of exosome therapies, Australia-based Exopharm Limited, supports the US Food & Drug Administration (FDA) in highlighting the health dangers of unapproved products peddled by clinics that are openly flouting the rules.
25 Oct, 2019
If you want to know who really controls Exopharm Limited (ASX:EX1), then you'll have to look at the makeup of its...